- Newsletter
- August 2025
Global
€2648EUR$2,995USD£2,286GBP
- Report
- July 2025
- 295 Pages
Global
From €4416EUR$4,995USD£3,813GBP
- Report
- June 2025
- 193 Pages
Global
From €4377EUR$4,950USD£3,778GBP
- Report
- October 2024
- 83 Pages
Global
From €4288EUR$4,850USD£3,702GBP
- Report
- January 2025
- 142 Pages
Asia Pacific
From €2873EUR$3,250USD£2,481GBP
- Report
- July 2025
- 150 Pages
United States
From €5261EUR$5,950USD£4,542GBP
- Report
- July 2025
- 120 Pages
United States
From €5261EUR$5,950USD£4,542GBP
- Report
- July 2025
- 100 Pages
United States
From €5261EUR$5,950USD£4,542GBP
- Report
- June 2025
- 90 Pages
United States
From €3492EUR$3,950USD£3,015GBP
- Report
- June 2025
- 85 Pages
United States
From €3095EUR$3,500USD£2,672GBP
- Report
- January 2025
- 140 Pages
Asia Pacific
From €3537EUR$4,000USD£3,053GBP
- Report
- October 2024
- 134 Pages
North America
From €3537EUR$4,000USD£3,053GBP
- Report
- June 2025
- 300 Pages
Latin America
From €3421EUR$3,869USD£2,953GBP
- Report
- April 2025
- 163 Pages
Europe
From €3050EUR$3,450USD£2,633GBP
- Report
- April 2025
- 161 Pages
Asia Pacific
From €3050EUR$3,450USD£2,633GBP
- Report
- April 2025
- 142 Pages
North America
From €3050EUR$3,450USD£2,633GBP
- Report
- April 2025
- 150 Pages
Middle East, Africa
From €3050EUR$3,450USD£2,633GBP
- Report
- June 2025
- 95 Pages
Asia Pacific
From €3492EUR$3,950USD£3,015GBP
- Report
- June 2021
- 123 Pages
Global
From €1147EUR$1,297USD£990GBP
- Report
- July 2020
- 269 Pages
Global
From €3092EUR$3,497USD£2,669GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more